CDR-132L is under clinical development by Cardior Pharmaceuticals and currently in Phase II for Congestive Heart Failure (Heart Failure). According to GlobalData, Phase II drugs for Congestive Heart Failure (Heart Failure) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CDR-132L’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CDR-132L is under development for the treatment of stable heart failure of ischemic origin with reduced left ventricular ejection fraction after myocardial infraction. The drug candidate is administered through intravenous and subcutaneous routes. It acts by targeting microRNA-132 (miR132).
Cardior Pharmaceuticals overview
Cardior Pharmaceuticals (Cardior) is a research based biopharmaceutical company which discovers, develops, manufactures, and commercializes RNA therapeutics for cardiovascular disease patients. It serves various markets including medical clinics and hospitals, pharmaceuticals, and retail clinics. Cardior is headquartered in Hannover, Niedersachsen, Germany.
For a complete picture of CDR-132L’s drug-specific PTSR and LoA scores, buy the report here.